yh32367

mAbexperimentalBi-specific

Clinical trial activity

1 trials · 15 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Aug 26, 2022 (NCT05523947)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05523947Phase 1/Phase 2 (Phase 2)Aug 26, 2022Ajou University, Austin Health, Catholic University of Korea, Cha Medical University, Chonbuk National University, Gyeongsang University, Harvard University, Korea University, Seoul National University, Southern Oncology Clinical Research Unit, Sungkyunkwan University, University of Ulsan, Vanderbilt University, Yonsei University, Yuhan Pharmaceutical Company
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ajou UniversityAcademic/Hospital1012022
Austin HealthAcademic/Hospital1012022
Catholic University of KoreaAcademic/Hospital1012022
Cha Medical UniversityAcademic/Hospital1012022
Chonbuk National UniversityAcademic/Hospital1012022
Gyeongsang UniversityAcademic/Hospital1012022
Harvard UniversityAcademic/Hospital1012022
Korea UniversityAcademic/Hospital1012022
Seoul National UniversityAcademic/Hospital1012022
Southern Oncology Clinical Research UnitFor profit1012022
Sungkyunkwan UniversityAcademic/Hospital1012022
University of UlsanAcademic/Hospital1012022
Vanderbilt UniversityAcademic/Hospital1012022
Yonsei UniversityAcademic/Hospital1012022
Yuhan Pharmaceutical CompanyFor profit1112022
15 organizations
Page 1 / 1